Articles tagged with Hormone Therapy
A study published by the American Academy of Neurology found that estradiol therapy via skin patches maintained brain volume and reduced amyloid plaque deposits in women. Meanwhile, estrogen pills caused greater structural changes in the brain, which stopped once treatment was stopped.
New mouse studies show that tamoxifen and raloxifene improve cardiac, respiratory, and skeletal muscle functions while increasing bone density in muscular dystrophy models. The treatments delay or halt disease progression, reducing muscle pathology and inflammation.
A large population-based study found that patients on levothyroxine had lower quality of life and more comorbidity than those not taking the hormone. The study also showed that comorbidity had a greater negative impact on the quality of life of LT4 users.
Immunotherapy has shown promising results in treating metastatic breast cancer, with a median progression-free survival of 33 months and median overall survival of 82 months. The treatment has been found to improve PFS and OS in both luminal and non-luminal subtypes, offering new hope for patients with this incurable disease.
The study found that nearly half of the wives reported that their partner's health problem affected their own health, with many feeling increasingly socially isolated. The women also expressed concerns about the role change in their relationship as their husbands became less able to fulfill their usual roles.
A clinical trial found that vaginal estrogen tablets, moisturizers, and a placebo gel all improved vaginal discomfort symptoms. However, the study suggests that better treatment options are needed for postmenopausal women, who experience significant quality-of-life effects from these symptoms.
The Endocrine Society has released updated guidelines for testosterone prescribing practices, recommending reserving therapy for men with well-documented hypogonadism. The guidelines also suggest individualizing treatment decisions for older men and avoiding routine testing for healthy men.
A new class of experimental drugs has been found to reduce hot flushes in menopausal women by almost three-quarters within three days. The treatment also improves sleep and concentration significantly. The compound works by blocking the action of a brain chemical called neurokinin B, which triggers hot flushes.
A study published in PLOS ONE found that menopausal hormone therapy is not associated with adverse changes in cardiac structure and function, but may be linked to some healthier heart characteristics. The research examined 1,604 post-menopausal women and found significantly smaller left ventricular and left atrial chamber volumes.
A recent study published in Endocrine Practice found that only a quarter of transgender women could lower their testosterone levels within the female range using spironolactone and estrogen therapy. The researchers identified four groups with varying degrees of testosterone suppression, highlighting the need for further studies to unde...
Researchers at Dana-Farber Cancer Institute have identified a specific mechanism by which estrogen receptor-positive breast cancers become resistant to standard therapies and metastasize. DNA mutations in the estrogen receptor gene cause tumors to grow even without estrogen, leading to treatment-resistant disease.
Researchers from Brigham and Women's Hospital have identified unique stroke risk factors in women, including early age of menarche, low levels of dehydroepiandrosterone hormone, and oral estrogen use. The study emphasizes the need for clinicians to consider these factors, particularly in women with a history of pregnancy complications.
The Clinical Pharmacogenetics Implementation Consortium has published the first-ever clinical practice guideline for using CYP2D6 genotype to guide tamoxifen therapy in women with early-stage estrogen receptor-positive breast cancer. The guidelines recommend alternative hormonal therapies based on CYP2D6 genotype, aiming to improve tre...
Researchers have discovered a link between male sex hormone levels and vitamin D metabolism that may be targeted to treat osteoporosis in men undergoing prostate cancer therapy. Progesterone receptor blockers could enhance the effectiveness of vitamin D supplements, reducing bone fracture risks.
Researchers identified a guardian molecule triggered by testosterone that protects males from disease. Treatment with the molecule eliminated symptoms in female mice, offering hope for new MS therapies.
Researchers at the University of Edinburgh identified a key protein driving repair of the womb lining during menstruation, which is reduced in women with heavy periods. Boosting levels of this protein shows promise as a novel, non-hormonal treatment to reduce blood loss and improve tissue repair.
A Yale-led study reveals the intricate mechanism of beta-Klotho, a protein that regulates longevity and metabolism. The findings could lead to therapies for diabetes, obesity, and certain cancers.
A study found that hormone therapy can alleviate eating disorder symptoms in transgender individuals, particularly those who identify as female. The research, which analyzed over 560 patients, suggests that hormone treatment improves body satisfaction and reduces perfectionism, anxiety, and depression.
A year-long hormone therapy was more effective than placebo in preventing the onset of depressive symptoms among women without depression during menopause transition and early postmenopause. Women with recent stressful life events showed the greatest mood benefit from hormone therapy.
Researchers found that estrogen treatment exerts positive effects on immune cells in the brain and oligodendrocytes, providing complementary actions that protect against MS damage. Estrogen's protective effect is mediated by protein ERb, targeting both cell types for disease prevention.
Researchers discovered that a hormone therapy combination of conjugated estrogens and bazedoxifene improves metabolism, prevents weight gain, and reduces inflammation in the liver. The treatment also showed no increased risk of reproductive cancer.
Researchers have identified a potential therapeutic target for aggressive breast cancer cells lacking estrogen receptor alpha, but expressing estrogen receptor beta. Estrogen or estrogen-like chemicals can slow tumor growth and even cause regression in these cells, which could lead to new treatment options.
The USPSTF has updated its recommendation statement on the use of hormone therapy in postmenopausal women, citing uncertain evidence on whether menopause increases the risk of chronic conditions. The organization recommends against combined estrogen and progestin hormone therapy or estrogen alone for primary prevention.
A Phase III trial led by MD Anderson Cancer Center found that talazoparib, a PARP inhibitor, extends progression-free survival and improves quality-of-life measures for patients with metastatic HER2-negative breast cancer and BRCA1/2 mutations. Talazoparib was associated with a 46% lower risk of progression compared to chemotherapy.
Researchers developed lab-engineered ovaries that improve bone and uterine health, body composition, and are more effective than hormone drugs in an animal model. The treatment could provide a safer, more natural alternative to hormone replacement medications.
A Yale-led study shows that thyroid hormone therapy significantly resolves fibrosis in the lungs of mice, leading to increased survival. The researchers found that normalizing mitochondria function in epithelial cells protects them from damage and allows resolution of fibrosis.
A new article reviews options for treating genitourinary syndrome of menopause, including low-dose vaginal estrogen therapy and pelvic floor physical therapy. Despite the availability of effective treatments, lack of awareness among healthcare providers and patients hinders reaching women with this condition.
Postmenopausal hormone therapy is not linked to increased risk of stroke if initiated within five years of menopausal onset. However, there may be an increased risk for haemorrhagic stroke with certain therapies containing conjugated equine oestrogens.
A protein called tyrosine kinase 6 (PTK6) has been identified as a potential therapeutic target for estrogen receptor positive (ER+) breast cancer. PTK6 promotes cancer cell survival and growth in ER+ breast cancer cells, making it a promising avenue for developing new treatments.
A new study supports the view that increased lifetime exposure to estrogen is linked to a reduced risk of developing glaucoma. Women who took estrogen-only hormone replacement therapy after ovary removal had a lower risk of developing glaucoma.
A recent study found that women who stopped taking bisphosphonates for over two years had a substantially increased risk of hip fractures compared to those who continued their treatment. The study, which analyzed data from 156,236 women, showed that the longer the duration of the drug holiday, the higher the risk of hip fracture.
A new USC-led study suggests that estrogen treatment after menopause can mitigate the negative effects of stress on working memory. Women taking estrogen-only therapy had lower cortisol levels and better performed on tests following exposure to stress compared to those receiving a placebo.
A small-scale study suggests estrogen treatment after menopause can protect working memory needed for short-term cognitive tasks from the effects of stress. Women who received estrogen therapy performed better on memory tasks regardless of stress exposure.
Researchers found that combining targeted drugs with hormone therapy results in a significant increase in the risk of severe or life-threatening adverse events. Most of these side effects are treatable and potentially preventable.
A recent study examined the impact of scheduling IVF procedures on weekends versus weekdays. The results showed that delays of two days or longer may be unfavorable in some treatments, but may not affect live-birth rates for most IVF/ICSI treatments receiving single-embryo transfer.
A new study found that insurance disparities account for a substantial proportion of the excess risk of death from breast cancer faced by black women. Improving access to care could address much of the existing black/white disparity in breast cancer mortality.
Scientists are learning how too little body fat damages the cardiovascular system, similar to obesity. Leptin replacement therapy shows promise in reducing cardiovascular risk and improving metabolic function in individuals with congenital lipodystrophy and other conditions.
A new study confirms that postmenopausal women prefer less proven options to hormone therapy for treating debilitating symptoms like hot flashes. Women are more willing to use exercise and herbal supplements over hormone therapy, despite acknowledging its effectiveness.
A new study analyzing Women's Health Initiative (WHI) data found no significant association between migraines and cardiovascular disease events, or an increased risk of heart disease with hormone therapy. Hormone therapy remains a viable treatment option for menopause symptoms in women with migraines.
Compounded bioidentical hormone therapies are not FDA-approved, lack quality control, and have the same risks as FDA-approved hormone therapy products. Women often unknowingly choose these over FDA-approved options due to misconceptions about safety and efficacy.
Theranostics combines predictive biomarkers and precise therapy to target cancer cells, minimizing side effects. The field is expected to change nuclear medicine from 'nuclear radiology' to true 'nuclear medicine,' with potential for cures.
The Endocrine Society provides guidelines for treating gender-dysphoric individuals, emphasizing the importance of multidisciplinary teams and informed consent. The recommended treatment includes hormone therapy to suppress sex hormone secretion and maintain normal levels for the person's affirmed gender.
Long-term follow-up of postmenopausal women using hormone therapy found no association with overall or cause-specific mortality. The study, published in JAMA, analyzed data from the Women's Health Initiative trials and included over 27,000 participants.
A new study led by Brigham and Women's Hospital found no association between hormone therapy and all-cause mortality, cardiovascular disease, or other major illnesses. However, younger women who received hormone therapy showed a trend toward reduced mortality rates compared to older women.
A new study found that hormone replacement therapy (HRT) can slow the decline in lung function in middle-aged women. Women who took long-term HRT performed better in lung function tests than those who never took HRT, losing an average of 46 ml less of lung volume over 20 years.
The MONARCH 3 trial showed that adding abemaciclib to endocrine therapy improved progression-free survival compared to endocrine therapy alone. Around one-third of women may not need a CDK 4/6 inhibitor as initial treatment.
The STAMPEDE trial presents late-breaking results from two new treatments for patients with high risk prostate cancer. Patients starting long-term hormone therapy may benefit equally from docetaxel and abiraterone acetate plus prednisolone, with both treatments providing a survival advantage over standard care alone.
Researchers found that anti-hormone therapy can activate DNA repair enzyme PARP, causing cancer cells to become more aggressive. Combining PARP inhibitors with anti-hormone therapy treatment may help reduce prostate cancer recurrence and increase survival rates.
A study found that transdermal estrogen therapy improved sexual function in early postmenopausal women, but oral conjugated equine estrogens did not show the same benefits. The treatment also reduced pain and increased lubrication compared to placebo.
A comprehensive review highlights the importance of lifestyle modifications and emerging approaches to manage menopausal symptoms after breast cancer. Non-pharmacologic therapies and several promising emerging agents show promise for symptom relief with reduced breast cancer risk.
A recent study found that tumor-infiltrating immune cells, specifically regulatory T cells (Tregs), can interfere with immune-targeting therapies in aggressive breast cancers. Depleting Tregs delayed tumor growth in mouse models, suggesting a potential strategy to improve targeted treatments.
A new study published in Menopause found that vaginal estrogen therapy does not increase the risk of cardiovascular disease, cancer, or other health issues in post-menopausal women. The research suggests that vaginal estrogen is a safe treatment for genitourinary symptoms associated with menopause.
A new study shows significant improvement in sexual and urinary function as well as quality of life for hypogonadal men undergoing long-term testosterone replacement therapy. Testosterone therapy is found to increase bladder emptying, improve erectile/sexual health and overall quality of life.
Teriparatide therapy increases osteoblast activity and lifespan, but stopping treatment leads to increased fat cell formation in mice. This suggests therapies targeting parathyroid hormone receptors may prioritize osteoblast development over other cell fates.
Researchers at UCLA found that estrogen therapy's dose, not delivery method, affects risk and benefit for postmenopausal women. Higher doses of conjugated equine estrogen are associated with greater risk of heart disease and certain cancers, especially in obese women.
New narrative review calls for additional research to better understand cardiovascular disease (CVD) and risk factors in transgender individuals receiving long-term cross-sex hormone therapy. Studies suggest worsening cardiovascular risk factors in transgender men and increased thromboembolic risk in transgender women.
A study by St. Jude Children's Research Hospital found that abdominal radiation increases the risk of premature ovarian insufficiency in female cancer survivors, which can lead to infertility and poor overall health. Researchers recommend estrogen replacement therapy to mitigate these risks.
A clinical trial of nearly 2,000 men shows that adding abiraterone acetate to standard therapy for high-risk, advanced prostate cancer lowers the relative risk of death by 37% and increases the 3-year survival rate to 83%. The treatment also reduces the chance of relapse by 70% and serious bone complications by 50%.
The STAMPEDE trial found that adding abiraterone to standard hormone therapy improves prostate cancer survival in men with high-risk disease. The drug reduced disease progression by 70% and severe bone complications by more than half, leading to a 40% increase in overall survival.
Researchers at Northwestern University have created bioprosthetic mouse ovaries using 3D printing, which not only ovulate but also give birth to healthy pups. The study's findings suggest that scaffold architecture plays a crucial role in follicle survival, paving the way for potential human applications.